Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280
4 hours ago
- #type 2 diabetes
- #GLP-1 receptor agonists
- #weight management
- GLP-1/GIP dual agonists showed the greatest weight loss compared to other weight management medications.
- Exposure-adjusted mortality risk was lower in most GLP-1 trials, with GLP-1/GIP RAs having the lowest rate ratio (RR: 0.1).
- Postmarketing reports indicated neoplasms were most frequent with weight management GLP-1 RAs (5.4%) and least with GLP-1/GIP RAs (0.7%).
- Efficacy outcomes were favorable for GLP-1-based therapies, but safety signals require further real-world evidence due to limited sample sizes.